19
Jul
2010
16
Jul
2010
13
Jul
2010
12
Jul
2010
22
Jun
2010
Posted in I - Series B, Q - 2Q10, R - INTERNATIONAL, X - Metabolism, X - Oncology
Aquinox Pharmaceuticals (Canada) a preclinical-stage small-molecule drug company focused on cancer, immune disorders and metabolic disease, closed a $25M Series B financing. Participants include Ventures West Capital, Johnson & Johnson Development Corp., Baker Brothers Investments, BC Advantage Funds and Pfizer Venture Investments.
15
Jun
2010
Posted in I - Series A, Q - 2Q10, R - INTERNATIONAL, X - Charcot-Marie-Tooth
Pharnext (France) a preclinical-stage biopharmaceutical company focused on treatment for Charcot-Marie-Tooth and other neuromuscular diseases, closed a $5.8M Series A financing. Participants include Truffle Capital, Aurinvest Capital and Financière Boscary.
10
Jun
2010
09
Jun
2010
Posted in I - Series D, Q - 2Q10, R - INTERNATIONAL, X - HIV, X - Hepatitis C, X - Oncology
Cytheris (France) a clinical-stage biopharmaceutical immune modulation company focused on HIV, HCV and oncology, closed a $14.3M Series D financing. Participants include CDC Entreprises, Gestion, Caisse de dépôt et Placement du Québec, CDC Innovation, Crédit Agricole Private Equity and Forbion Capital Partners.
27
May
2010
18
May
2010
Posted in I - Series B, Q - 2Q10, R - INTERNATIONAL, X - Device (Mass Spec)
Caprotec Bioanalytics (Germany) a commercial-stage company focused on a mass spec technology of multifunctional small molecules used to target, capture and isolate proteins based on their functionality, closed a $4.9M Series B financing. Participants include Creathor Venture, IBB Beteiligungsgesellschaft and ERP Startfonds.